To evaluate the association of second trimester cervicovaginal quantitative fetal fibronectin (qfFN) for predicting the risk of spontaneous preterm birth (sPTB) in a high-risk asymptomatic population. STUDY DESIGN: The EQUATE trial was a prospective observational study of asymptomatic patients at high risk for sPTB based on a previous sPTB, twin gestation, short cervical length (25 mm), and/ or prior cervical surgery. The study was conducted across 16 US sites from Nov 2013 to Oct 2016. A single qfFN specimen was collected by speculum examination from each subject between 16-0/7 and 21-6/7 weeks along with demographic/clinical data and pregnancy/neonatal outcomes. Outcome measures were the rates of sPTB at <35 and <32 weeks in women stratified by qfFN concentration. Data are shown for fFN by (i) <10, (ii) 10-199, (iii) 200-499, and (iv) 500 ng/mL. Treating physicians were blinded to the qfFN results. This study utilized investigational use qfFN, which is not currently FDA approved. RESULTS: 1,644 subjects were enrolled; 1,546 (94%) were evaluable and included in the final analysis. The overall sPTB rate was 13.4% (207/1546) <35 week and 6.2% (96/1546) <32 weeks. Within the study population, 60% stratified to the lowest fFN group of <10 ng/ mL, 34% within 10-199 ng/mL, 4.7% within 200-499 ng/mL, and 1.3% to the highest group of 500 ng/mL. sPTB rates <35 and <32 weeks were associated with increasing concentrations of fFN in a dose-dependent fashion (Table) , with similar results being observed across the various high-risk subgroups. The likelihood ratio (LR) of sPTB increased as qfFN increased, with LRs of delivery <32 weeks for 500 ng/mL of 6.0 (95% CI, 2.4-15.2) for the study population as a whole, while in twins the LR increased to 27.3 (95% CI, 5.5-136.2). The survival curve (Figure) shows a dose-response relationship between a single qfFN measurement at 16-22 weeks and subsequent risk of sPTB in twin gestations. CONCLUSION: This blinded, multicenter US study demonstrates that increasing cervicovaginal qfFN levels at 16-22 weeks were associated with an elevated risk of sPTB in a high-risk asymptomatic population, with an even greater positive association in twin pregnancies.
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546 Neurodevelopmental outcomes in late preterm and early term deliveries following antenatal corticosteroid exposure Eve Overton, Caitlin Baptiste, Cynthia Gyamfi-Bannerman Columbia University Irving Medical Center, New York, NY OBJECTIVE: Administration of Antenatal corticosteroids (ACS) is a well-established means of improving survival and decreasing morbidity with evidence of neuroprotective effect in children born prior to 34 weeks. ACS also decrease short term respiratory outcomes in the late preterm period. However, recent literature has challenged the benefit of ACS at greater than 34 weeks due to potential negative effects of ACS on neurocognitive development at later gestational ages. We chose to assess whether delivery beyond 34 weeks after early steroid exposure was associated with adverse neurocognitive outcomes in a population at a high risk of preterm delivery. STUDY DESIGN: We conducted a secondary analysis of a multicenter, randomized controlled trial of magnesium for neuroprotection in 
